ArticleCommunications medicine2025
Changes of in-vivo markers of platelet activation during the menstrual cycle in healthy pre-menopausal female individuals.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development.Molecular biology reports · 2026Review
- Estrous cycle-dependent changes in platelet indices in healthy mares.Veterinary research communications · 2026Article
- Progesterone-Dependent Changes in Platelet Activation Without Morphological Variation in Diestrus Mares.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSex differences in cardiovascular diseases (CVD) are a matter of immediate concern, with platelets playing a pivotal role as major contributors to CVD. While the protective effects of estrogens on vascular health have been largely investigated, the impact of endogenous reproductive hormones on platelet function is less clear. In the SHOW (Sexual Hormones and Hemostasis: Observations for Women Health) study, we aimed to assess the association between the levels of endogenous reproductive hormones and in-vivo platelet activation among pre-menopausal healthy female subjects.
methodsSerum levels of estradiol, progesterone (PG), testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and in vivo platelet activation markers were quantified at four time-points across the menstrual cycle (day (d) 1, d5 ± 2, d14 ± 2, and d21 ± 2).
resultsAmong 21 healthy participants (mean age: 30 years), significant variations of thromboxane B2 (TxB2), soluble P-selectin (sP-selectin) and soluble NOX2-derived peptide (sNOX2-dp) are detected across the menstrual cycle. Linear mixed model analysis shows that sP-selection is associated with LH levels (F = 6.400, p = .016) in a time-dependent manner. TxB2 is associated with FSH across all time-points (F = 6.051, p = .019) and is significantly reduced on d1 in individuals with self-reported heavy menstrual bleeding. Soluble CD40L (sCD40L) changes most significantly in individuals with an ovulatory cycle (i.e. PG ≥ 3 ng/ml at d21).
conclusionsIn healthy pre-menopausal female subjects, changes of in-vivo platelet activation markers are associated with changes of PG and gonadotropins. These findings suggest the need for caution in the interpretation of platelet biomarkers in clinical studies enrolling pre-menopausal female individuals.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.